Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ECL stock price vs BMY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMY's multiple
Needs BMY P/E.
Implied fair value · at ECL's multiple
Needs ECL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ECOLAB INC. · implied price per share
Bear
$44.93
Base
$57.49
Bull
$73.86
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$50.67
Base
$61.69
Bull
$77.14
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Procter & Gamble Company
ECL vs PG
COLGATE PALMOLIVE CO
ECL vs CL
CLOROX CO /DE/
ECL vs CLX
KIMBERLY CLARK CORP
ECL vs KMB
Pfizer Inc.
ECL vs PFE
Merck & Co., Inc.
ECL vs MRK
AbbVie Inc.
ECL vs ABBV
Eli Lilly and Company
ECL vs LLY
Amgen Inc.
ECL vs AMGN
Gilead Sciences, Inc.
ECL vs GILD
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ECL can sustain its current premium despite only moderate growth and middling quality scores, then hold or underweight rather than add because BMY comparison and DCF range both imply substantial downside from $256.02.
ECL trades at a clear premium to BMY on earnings, sales, and enterprise value multiples, while the model-implied price of $120.35 is far below the current $256.02 share price. The gap is driven by ECL’s much richer P/E, P/S, EV/EBITDA, and EV/Revenue multiples versus BMY, despite only modestly better revenue growth.
Supporting Metrics
